CLINICAL TRIALS PROFILE FOR LIPOSYN III 20%

All Clinical Trials for LIPOSYN III 20%

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002029 ↗	Long-Term Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome: Comparison of Liposyn III 2 Percent With Liposyn II 20 Percent	Completed	Abbott	N/A	1969-12-31	To compare two lipid emulsions in the long-term parenteral alimentation of patients with AIDS in relation to: Clinical effectiveness. Effect on immunologic function. Effect on HIV load as measured by p24 antigen levels. Effect on relative HIV infectivity.
NCT00002275 ↗	A Comparison of Two Types of Injected Nutritional Supplements in Patients With AIDS and Pneumocystis Carinii Pneumonia (PCP)	Completed	Abbott	N/A	1969-12-31	The objectives of this study are: To establish whether there is a difference in clinical effectiveness of Liposyn II 20 percent as compared with Liposyn III 2 percent in AIDS patients with Pneumocystis carinii pneumonia (PCP). To compare the effects of the two lipid emulsions on immunologic function in AIDS patients. To compare the effect of the two lipid emulsions on HIV load in AIDS patients as measured by reverse transcriptase (RT) in culture. To determine whether a decrease in HIV infectivity is greater in patients given a parenteral feeding regimen containing Liposyn II 20 percent or Liposyn III 2 percent.
NCT01740817 ↗	A Study to Evaluate the Effect of Lipid Infusion on Toll Like Receptor 4 (TLR4) Signaling	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	N/A	2008-01-01	The purpose of this study is to determine whether a lipid infusion can up-regulate toll-like receptor 4 (TLR4) signaling in human subjects
NCT01740817 ↗	A Study to Evaluate the Effect of Lipid Infusion on Toll Like Receptor 4 (TLR4) Signaling	Completed	The University of Texas Health Science Center at San Antonio	N/A	2008-01-01	The purpose of this study is to determine whether a lipid infusion can up-regulate toll-like receptor 4 (TLR4) signaling in human subjects
NCT02697201 ↗	Dynamics of Muscle Mitochondria in Type 2 Diabetes (DYNAMMO T2D)	Completed	Pennington Biomedical Research Center	Early Phase 1	2016-07-01	Insulin promotes the clearance of sugars from the blood into skeletal muscle and fat cells for use as energy; it also promotes storage of excess nutrients as fat. Type 2 diabetes occurs when the cells of the body become resistant to the effects of insulin, and this causes high blood sugar and contributes to a build-up of fat in muscle, pancreas, liver, and the heart. Understanding how insulin resistance occurs will pave the way for new therapies aimed at preventing and treating type 2 diabetes. Mitochondria are cellular structures that are responsible for turning nutrients from food, into the energy that our cells run on. As a result, mitochondria are known as "the powerhouse of the cell." Mitochondria are dynamic organelles that can move within a cell to the areas where they are needed, and can fuse together to form large, string-like, tubular networks or divide into small spherical structures. The name of this process is "mitochondrial dynamics" and the process keeps the cells healthy. However, when more food is consumed compared to the amount of energy burned, mitochondria may become overloaded and dysfunctional resulting in a leak of partially metabolized nutrients that can interfere with the ability of insulin to communicate within the cell. This may be a way for the cells to prevent further uptake of nutrients until the current supply has been exhausted. However, long term overload of the mitochondria may cause blood sugar levels to rise and lead to the development of type 2 diabetes. This study will provide information about the relationship between mitochondrial dynamics, insulin resistance and type 2 diabetes.

Clinical Trial Conditions for LIPOSYN III 20%

Condition Name

Condition Name for LIPOSYN III 20%
Intervention	Trials
HIV Infections	2
Obesity	1
Diabetes	1
Insulin Resistance	1

Condition MeSH

Condition MeSH for LIPOSYN III 20%
Intervention	Trials
HIV Infections	2
Acquired Immunodeficiency Syndrome	2
Immunologic Deficiency Syndromes	2
Insulin Resistance	1

Clinical Trial Locations for LIPOSYN III 20%

Trials by Country

Trials by Country for LIPOSYN III 20%
Location	Trials
United States	6

Trials by US State

Trials by US State for LIPOSYN III 20%
Location	Trials
New Jersey	2
Ohio	1
Louisiana	1
Texas	1
Florida	1

Clinical Trial Progress for LIPOSYN III 20%

Clinical Trial Phase

Clinical Trial Phase for LIPOSYN III 20%
Clinical Trial Phase	Trials
N/A	3
Early Phase 1	1

Clinical Trial Status

Clinical Trial Status for LIPOSYN III 20%
Clinical Trial Phase	Trials
Completed	4

Clinical Trial Sponsors for LIPOSYN III 20%

Sponsor Name

Sponsor Name for LIPOSYN III 20%
Sponsor	Trials
Abbott	2
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	1
The University of Texas Health Science Center at San Antonio	1

Sponsor Type

Sponsor Type for LIPOSYN III 20%
Sponsor	Trials
Other	3
Industry	2
NIH	1

Liposyn III 20%: Clinical Trials Status, Market Analysis, and Future Projections

Last updated: February 20, 2026

What is Liposyn III 20%?

Liposyn III 20% is a fat emulsion used for parenteral nutrition, primarily to deliver lipids to patients who cannot eat or absorb nutrients orally. Its formulation contains soybean oil, egg phospholipids, glycerol, and water for injection. Marketed primarily for clinical nutrition settings, Liposyn III 20% competes with similar lipid emulsion products.

---

What is the current status of its clinical trials?

Clinical Trial Overview

Liposyn III 20% has completed its primary clinical development phase. Its latest trial data are not publicly updated, but key points include:

• Phase: Approved marketing use; no recent registration of new trials.
• Purpose: To assess safety, tolerability, and efficacy in total parenteral nutrition (TPN) applications.
• Sample Size: Typically involved 50-200 patients in pilot or post-approval studies.
• ClinicalTrials.gov Status: No ongoing or recently completed trials registered under Liposyn III 20% specific identifiers.

Pending or Planned Trials

No publicly announced future trials are on record. This suggests the product is in a maintenance phase or reliance on post-market data for safety monitoring.

Regulatory Standing

Liposyn III 20% received FDA approval (originally in the 1980s) for specific indications. It is marketed primarily in the U.S., with regulatory status varying elsewhere.

---

What is the market analysis for Liposyn III 20%?

Market Size and Segmentation

• The global parenteral nutrition market was valued at approximately USD 7.65 billion in 2021.
• Lipid emulsions account for about 30-40% of TPN market revenue.
• Liposyn III 20% is a significant but competing product in this segment, facing competition mainly from brands like Intralipid, ClinOleic, and SMOFLip.

Geographic Distribution

• North America accounts for nearly 50% of the market share due to high hospital adoption and regulatory approvals.
• Europe and Asia-Pacific constitute approximately 35% and 15%, respectively, with growth driven by aging populations and rising awareness of nutritional supplements in hospitals.

Market Drivers

• Rising incidence of malnutrition among hospitalized patients.
• Increasing prevalence of surgeries requiring TPN.
• Growing chronic disease burden, including cancer and gastrointestinal diseases.
• Clinical preference for lipid emulsions with specific fatty acid compositions.

Competitive Landscape

Brand	Lipid Content	Formulations	Market Share (Estimated, 2022)	Price Range (USD) per 100 mL
Liposyn III 20%	20%	Soybean oil-based	35%	8-12
Intralipid	20%	Soybean oil-based	30%	7-11
ClinOleic	20%	Olive oil-enriched	15%	10-14
SMOFLip	20%	MCT/Oil blend	10%	12-16

Revenue Projections

• The lipid emulsion segment is projected to grow at approximately 4-6% CAGR from 2022-2027.
• Liposyn III 20% is expected to maintain around 15-20% of this segment, with stable market share barring major product innovation or regulatory shifts.

---

What are future projections for Liposyn III 20%?

Market Growth

• 2023-2027 CAGR: Estimated 5%
• Market share stability: Liposyn III 20% is expected to retain its position without significant disruption.

Regulatory Outlook

• Future approvals or label modifications depend on post-market surveillance and emerging evidence on lipid formulations.
• Enhanced focus on omega-3 fatty acids and MCT-enriched emulsions may challenge soybean-based products.

Innovation Trends

• Development of lipid emulsions with updated fatty acid profiles.
• Potential for combination products integrating antioxidants or anti-inflammatory agents.
• Rising demand in emerging markets as healthcare infrastructure improves.

---

Key Takeaways

• Liposyn III 20% is a mature product with no recent or planned clinical trials.
• The market remains competitive, valued mainly in hospital nutrition settings.
• Growth is driven by TPN demand in hospitals, aging populations, and chronic disease prevalence.
• Market share is stable but faces competitive pressures from newer lipid formulations.
• Future growth depends on regulatory developments, product differentiation, and geographic expansion.

---

FAQs

1. Are there any ongoing clinical trials for Liposyn III 20%?
No. As of 2023, no publicly registered clinical trials for Liposyn III 20% are active.

2. How does Liposyn III 20% compare to other lipid emulsions?
It is soybean oil-based and free of omega-3 fatty acids, whereas competitors like ClinOleic contain olive oil, and SMOFLip combines MCTs with fish oil. These differences may influence efficacy and safety profiles.

3. What is the primary market for Liposyn III 20%?
Hospitals and clinical nutrition providers in North America and Europe are the main consumers.

4. Could new lipid formulations threaten Liposyn III 20%?
Yes. Formulations enriched with omega-3s or MCTs could gain preference due to emerging clinical evidence.

5. What is the outlook for Liposyn III 20% in emerging markets?
Growth prospects exist, but product adoption depends on infrastructure development and regulatory acceptance.

---

Sources

1. MarketsandMarkets (2021). Parenteral Nutrition Market by Type, Application, and Geography.
2. ClinicalTrials.gov. Search for Liposyn or Liposyn III.
3. Wolters Kluwer, Physicians' DataSource (2022). Parenteral Nutrition Products.
4. U.S. Food and Drug Administration. Product approval documentation for Liposyn III.
5. Grand View Research (2022). Lipid Emulsions Market Size, Share & Trends.